Yahoo
Stockholm - Free Realtime Quote SEK

Immunovia AB (publ) (IMMNOV.ST)

0.1628 -0.0012 (-0.73%)
As of 11:14:16 AM GMT+2. Market Open.
Chart Range Bar
Loading chart for IMMNOV.ST
  • Previous Close 0.1640
  • Open 0.1638
  • Bid 0.1628 x --
  • Ask 0.1640 x --
  • Day's Range 0.1620 - 0.1658
  • 52 Week Range 0.1502 - 0.7527
  • Volume 688,952
  • Avg. Volume 2,950,403
  • Market Cap (intraday) 109.51M
  • Beta (5Y Monthly) 2.65
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0800
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.43

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

www.immunovia.com

18

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 8/14/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

IMMNOV.ST
28.28%
OMX Stockholm 30 Index (^OMX)
13.51%

1-Year Return

IMMNOV.ST
63.14%
OMX Stockholm 30 Index (^OMX)
24.29%

3-Year Return

IMMNOV.ST
66.71%
OMX Stockholm 30 Index (^OMX)
48.52%

5-Year Return

IMMNOV.ST
99.54%
OMX Stockholm 30 Index (^OMX)
35.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 381k
Earnings -22.83M

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

0.43
0.43 Average
0.1628 Current
0.43 High

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    108.70M

  • Enterprise Value

    77.07M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    73.01

  • Price/Book (mrq)

    4.61

  • Enterprise Value/Revenue

    63.87

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -124.89%

  • Return on Equity (ttm)

    -426.97%

  • Revenue (ttm)

    1.21M

  • Net Income Avi to Common (ttm)

    -88.33M

  • Diluted EPS (ttm)

    -0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    34.9M

  • Total Debt/Equity (mrq)

    13.83%

  • Levered Free Cash Flow (ttm)

    -40.29M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: